Article History
Received: 26 April 2023
Accepted: 30 August 2023
First Online: 7 September 2023
Declarations
:
: NV: Research support (not related to this work) for clinical trials to the institution (MGH): Pfizer, Daehwa, Radius, Merck, Novartis. Advisory Board participation (not related to this work): OncoSec, AbbVie, Gilead, TerSera, Stemline. CY: Research funding (not related to this work) to the institution (UCSF): NCI and Quantum Leap Healthcare Collaborative. HSR: Institutional research support (not related to this work) from AMBRX; Astellas Pharma Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Pionyr Immunotherapeutics; and Seattle Genetics, Inc; Sermonix Pharmaceuticals Inc.; Taiho Oncology, Inc. and Veru Inc. Travel support to academic meetings (not related to this work) from Merck, Astra Zeneca and Gilead. Consultancy/advisory support (not related to this work) from Puma, NAPO and Blueprint.
: This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As this was an analysis of existing datasets, formal consent was not required. This article does not contain any studies with animals performed by any of the authors.
: This research only involved de-identified patient data from existing datasets.
: Institutional Review Board review and consent of patients was not required for this study as it involved analysis of publicly available de-identified datasets.